Literature DB >> 25145448

Effects of leukemia inhibitory receptor gene mutations on human hypothalamo-pituitary-adrenal function.

Tulay Guran1, Omer Guran, Cem Paketci, Osman Kipoglu, Irfan Firat, Serap Turan, Zeynep Atay, Belma Haliloglu, Abdullah Bereket.   

Abstract

BACKGROUND: Stuve-Wiedemann syndrome (STWS) (MIM #601559) is a rare autosomal recessive disorder caused by mutations in the leukemia inhibitory factor receptor (LIFR) gene. STWS has a diverse range of clinical features involving hematopoietic, skeletal, neuronal and immune systems. STWS manifests a high mortality due to increased risk of sudden death. Heterodimerization of the LIFR mediates leukemia inhibitory factor (LIF) signalling through the intracellular Janus kinase (JAK)/STAT3 signalling cascade. The LIF/LIFR system is highly expressed in and regulates the hypothalamo-pituitary-adrenal (HPA) axis.
OBJECTIVES: HPA function was investigated in three STWS patients to characterise consequences of impaired LIF/LIFR signalling on adrenal function.
DESIGN: Six genetically proven STWS patients from four unrelated Turkish families were included in the study. Sudden death occurred in three before 2 years of age. Basal adrenal function tests were performed by measurement of early morning serum cortisol and plasma ACTH concentrations on at least two different occasions. Low dose synacthen stimulation test and glucagon stimulation tests were performed to explore adrenal function in three patients who survived.
RESULTS: All patients carried the same LIFR (p.Arg692X) mutation. Our oldest patient had attenuated morning serum cortisol and plasma ACTH levels at repeated measurements. Two of three patients had attenuated cortisol response (<18 μg/dl) to glucagon, one of whom also had borderline cortisol response to low dose (1 μg) ACTH stimulation consistent with central adrenal insufficiency.
CONCLUSIONS: STWS patients may develop central adrenal insufficiency due to impaired LIF/LIFR signalling. LIF/LIFR system plays a role in human HPA axis regulation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25145448     DOI: 10.1007/s11102-014-0594-5

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  28 in total

1.  Deficit in anterior pituitary function and variable immune deficiency (DAVID) in children presenting with adrenocorticotropin deficiency and severe infections.

Authors:  Marie-Hélène Quentien; Brigitte Delemer; Dimitris T Papadimitriou; Pierre-François Souchon; Roland Jaussaud; Anne Pagnier; Martine Munzer; Nicolas Jullien; Rachel Reynaud; Noémie Galon-Faure; Alain Enjalbert; Anne Barlier; Thierry Brue
Journal:  J Clin Endocrinol Metab       Date:  2011-10-19       Impact factor: 5.958

2.  Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response.

Authors:  V Chesnokova; C J Auernhammer; S Melmed
Journal:  Endocrinology       Date:  1998-05       Impact factor: 4.736

3.  Leukemia inhibitory factor modulates interleukin-1beta-induced activation of the hypothalamo-pituitary-adrenal axis.

Authors:  C J Auernhammer; V Chesnokova; S Melmed
Journal:  Endocrinology       Date:  1998-05       Impact factor: 4.736

4.  Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway.

Authors:  D W Ray; S G Ren; S Melmed
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

5.  A common pro-opiomelanocortin-binding element mediates leukemia inhibitory factor and corticotropin-releasing hormone transcriptional synergy.

Authors:  C Bousquet; D W Ray; S Melmed
Journal:  J Biol Chem       Date:  1997-04-18       Impact factor: 5.157

6.  Leukemia inhibitory factor regulates proopiomelanocortin transcription.

Authors:  D W Ray; S G Ren; S Melmed
Journal:  Ann N Y Acad Sci       Date:  1998-05-01       Impact factor: 5.691

7.  Leukemia inhibitory factor as a regulator of steroidogenesis in human NCI-H295R adrenocortical cells.

Authors:  Irina V Mikhaylova; Tiina Jääskeläinen; Jarmo Jääskeläinen; Jorma J Palvimo; Raimo Voutilainen
Journal:  J Endocrinol       Date:  2008-09-16       Impact factor: 4.286

Review 8.  Cushing syndrome related to leukemic infiltration of the central nervous system: a case report and a possible role of LIF.

Authors:  Nursel Muratoglu Sahin; Zekai Avci; Baris Malbora; Ayhan Abaci; Sibel Tulgar Kinik; Namik Yasar Ozbek
Journal:  J Pediatr Endocrinol Metab       Date:  2013       Impact factor: 1.634

9.  Significance of low-dose and standard-dose ACTH tests compared to overnight metyrapone test in the diagnosis of adrenal insufficiency in childhood.

Authors:  E Nazli Gonc; Nurgun Kandemir; Sibel T Kinik
Journal:  Horm Res       Date:  2003

10.  Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion.

Authors:  S Akita; J Webster; S G Ren; H Takino; J Said; O Zand; S Melmed
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more
  4 in total

1.  Stüve-Wiedemann syndrome with a novel mutation in a Saudi infant.

Authors:  Jubara Alallah; Loujen Omar Alamoudi; Reham Mohmmed Makki; Aiman Shawli; Alaa T AlHarbi
Journal:  Int J Pediatr Adolesc Med       Date:  2021-10-09

Review 2.  Stüve-Wiedemann Syndrome: Update on Clinical and Genetic Aspects.

Authors:  Débora Romeo Bertola; Rachel S Honjo; Wagner A R Baratela
Journal:  Mol Syndromol       Date:  2016-03-16

3.  Cytoplasmic LIF reprograms invasive mode to enhance NPC dissemination through modulating YAP1-FAK/PXN signaling.

Authors:  Shu-Chen Liu; Tien Hsu; Yu-Sun Chang; An-Ko Chung; Shih Sheng Jiang; Chun-Nan OuYang; Chiou-Hwa Yuh; Chuen Hsueh; Ya-Ping Liu; Ngan-Ming Tsang
Journal:  Nat Commun       Date:  2018-11-30       Impact factor: 14.919

Review 4.  Clinical overview and outcome of the Stuve-Wiedemann syndrome: a systematic review.

Authors:  Hélène Warnier; Christophe Barrea; Sarah Bethlen; Isabelle Schrouff; Julie Harvengt
Journal:  Orphanet J Rare Dis       Date:  2022-04-23       Impact factor: 4.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.